SUO Annual Meeting

As stereotactic ablative radiation therapy enters further into the treatment space for metastatic RCC, integration of the approach is vital for physicians to focus on, according to Raquibul Hannan, MD, PhD.

Risk of tumor recurrence in the BLC Registry group was significantly lower than in patients who received WLC alone.

OS was also found to be prolonged in the propensity score matched analysis, with a median that was not reached in the pembrolizumab arm vs 21 months in the IRC arm.

Compared with data from the KEYNOTE-057 study, the use of pembrolizumab monotherapy in the real-world setting was similar in the treatment of patients with high-risk non-muscle invasive bladder cancer.

“This is the perfect situation for the development of biomarkers to inform [patient selection for] adjuvant treatment with immune checkpoint blockade,” says Matthew Galsky, MD.

In this interview, Curtis A. Pettaway, MD, reflects on what innovations and research led to his becoming the first Black recipient of the Society of Urologic Oncology’s Huggins Award.

"I was very early among the first women in urology, and in those days it was really going out on a limb to go into that field," said Eila C. Skinner, MD.

“Imaging advances with PSMA-directed modalities…are absolutely shifting the landscape,” says Alicia K. Morgans, MD, MPH.

“We…had 1 of the largest African American hereditary prostate cancer projects funded through the National Cancer Institute,” says Curtis A. Pettaway, MD.

“We’re [going to] have a whole new era of immune therapies and different novel ways to treat [patients], and then [utilize] combinations of these therapies,” says Michael S. Cookson, MD, MMHC, FACS.

“If you're thinking about urology, then what I would do is get exposure as early as possible,” says Curtis A. Pettaway, MD.

“As president of SUO, it's really rewarding to be able to hand these giants these great awards,” says Michael S. Cookson, MD, MMHC, FACS.

“I believe that this is, of course,…a harbinger of what is to come—those of underserved backgrounds being…featured [more] in our organizations,” says Curtis A. Pettaway, MD.

“The SUO has never been stronger in its ability to deliver on clinical trials,” says Michael S. Cookson, MD, MMHC, FACS.

"Although, as urologic oncologists, we all see a few cases in our practices individually, I think, no question, there's a lot of heterogeneity in how penile cancer is managed across the United States," says Philippe E. Spiess, MD, MS.

“We're really moving into not just these annual meetings, but we're going to have some programs throughout the year that will be targeted towards…really important, impactful research that comes out,” says Michael S. Cookson, MD, MMHC, FACS.

“New regimens should now start to be explored, both…single-agent drugs as well as combination therapies,” says Pavlos Msaouel, MD, PhD.

“[It’s] important to see all of these…clinically important endpoints going in the same direction,” says Matthew D. Galsky, MD.

“It was incredibly humbling,” says Eila C. Skinner, MD.

“This category of therapeutic is fairly well-tolerated; safe to give,” says Mohummad M. Siddiqui MD.

“We still debate and there’s some good data that [supports that] chemotherapy is not that effective for patients with penile cancer,” says Philippe E. Spiess, MD, MS, FACS.

“We’re just getting one step closer to being able to find urine tests that we can use to help risk stratify patients, and then help understand the genetic profiles of other tumors, which might help guide management later on,” says Wesley Yip, MD.

Pavlos Msaouel, MD, PhD, discusses the latest developments with adjuvant therapy in nonmetastatic renal cell carcinoma.

“We found that, overall, segmental ureterectomy patients actually did better in terms of overall survival,” says Siv Venkat, MD, FRCSC.

Urine cytology specimen NGS was found to be a feasible and valid method of assessing genomic alterations in patients with upper tract urothelial carcinoma.

Findings presented at the 2021 Society of Urologic Oncology Annual Meeting demonstrate that segmental ureterectomy may be comparable to radical nephroureterectomy.

The investigators found that the overall upstaging rate from re-TURBT to RC was 34.9%, with 31.0% upstaged in the NAC group and 37.0% in the no-NAC group (P = .584).

“[I focused on] why this such an important topic and how we might better counsel our patients,” says Kristen Scarpato, MD, MPH.

“One of the hardest things and one of the most important things is to figure out what part of urology excites you the most and look for those opportunities,” says Eila C. Skinner, MD.

"I think for the right patient, Cysview technology has a big deliverable,” says Alexander Kutikov, MD, FACS.